

Plandai Biotechnology, Inc.  
Form NT 10-Q  
May 15, 2015

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0058

Expires: August 31, 2015

Estimated average burden hours per response ... 2.50

000-51206

SEC FILE NUMBER

**FORM 12b-25**

**NOTIFICATION OF LATE FILING**

(Check one):  
 Form 10-K  
 Form 20-F  
 Form 11-K  
 Form 10-Q  
 Form 10-D  
 Form N-SAR  
 Form N-CSR

For Period Ended: March 31, 2015

- Transition Report on Form 10-K
- Transition Report on Form 20-F
- Transition Report on Form 11-K
- Transition Report on Form 10-Q
- Transition Report on Form N-SAR

For the Transition Period Ended:

*Read Instruction (on back page) Before Preparing Form. Please Print or Type.*

**Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.**

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

**PART I — REGISTRANT INFORMATION**

**PLANDAÍ BIOTECHNOLOGY, INC.**

---

Full Name of Registrant

---

Former Name if Applicable

**1451 North 200 East Suite #130C**

---

Address of Principal Executive Office (*Street and Number*)

**Logan, UT 84341**

---

City, State and Zip Code

**PART II — RULES 12b-25(b) AND (c)**

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

ý(a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

(c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

### PART III — NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

The Registrant has experienced a delay in completing the necessary disclosures and finalizing its financial statements with its independent public accountant in connection with its Quarterly Report on Form 10-Q for the period ended March 31, 2015 (the "Quarterly Report"). As a result of this delay, the Registrant was unable to file its Quarterly Report by the prescribed filing date of May 15, 2015 without unreasonable effort or expense.

### PART IV — OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

**ROGER DUFFIELD**    **801**            **209-1227**  
(Name)            (Area Code) (Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).  
Yes  No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion

thereof?

Yes  No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

**PLANDAÍ BIOTECHNOLOGY, INC.**

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 15, 2015 By: */s/ Roger  
Duffield*  
Name:  
Roger  
Duffield  
Title:  
Chief  
Executive  
Officer



